Compare National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares vs Twist Bioscience Corp — how do they compare? National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.27 (market cap $78.99B), while Twist Bioscience Corp trades at $138.07 (market cap $9.82B). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is far larger — about 8× Twist Bioscience Corp's market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays a 4.13% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NGG | TWST | |
|---|---|---|
Market Cap | $78.99B | $9.82B |
Volume | 740,402 | 2,115,226 |
Sector | Utilities | Health |
52-Week High | $93.93 | $205.00 |
52-Week Low | $73.54 | $25.45 |
Enterprise Value | $137.22B | $9.75B |
Dividend Yield | 4.13% | — |
Typical Hold Time | — | 27 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
TWST trades at $151.33, down 0.35% today, near its consensus price target of $153.70. The stock shows a bullish technical signal despite recent earnings misses, with revenue growth improving from $204M in 2022 to $377M in 2025. However, profitability remains a challenge with a net income margin of -31.66% and negative cash flows. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, fueling investor optimism in the healthtech sector.
The outlook balances strong revenue growth and AI partnerships against persistent losses and high valuation multiples. Investment appeal hinges on the company's ability to translate top-line expansion into profitability, with analyst consensus leaning bullish but execution risks remaining elevated for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares
National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
